RAPP
Rapport Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.80B
P/E Ratio
—
EPS
$-2.60
Beta
—
52W High
$42.27
52W Low
$7.73
50-Day MA
$33.85
200-Day MA
$27.91
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. is an innovative biotechnology firm focused on creating transformative therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and associated cognitive disorders. Leveraging proprietary drug candidates and advanced technology platforms, the company aims to push the frontiers of neuroscience through rigorous scientific research and clinical validation. By addressing critical unmet medical needs, Rapport Therapeutics is well-positioned to contribute to meaningful advancements in treatment options, thereby offering hope to patients suffering from debilitating cognitive impairments.
Fundamentals
| Revenue (TTM) | $20.00M |
| Gross Profit (TTM) | $6.86M |
| EBITDA | $-121.21M |
| Operating Margin | -121.10% |
| Return on Equity | -28.30% |
| Return on Assets | -19.10% |
| Revenue/Share (TTM) | $0.48 |
| Book Value | $9.86 |
| Price-to-Book | 3.83 |
| Price-to-Sales (TTM) | 90.20 |
| EV/Revenue | 66.9 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $47.83M |
| Float | $31.34M |
| % Insiders | 4.65% |
| % Institutions | 109.22% |
Historical Volatility
HV 10-Day
48.48%
HV 20-Day
57.02%
HV 30-Day
56.46%
HV 60-Day
56.73%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($57.10 target)
1
Strong Buy10
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026